Farhad Koohpeyma - Endocrine and Metabolism Research Center, Shiraz University of Medical Science, Shiraz, Iran
Samaneh Taghiyan - Endocrine and Metabolism Research Center, Shiraz University of Medical Science, Shiraz, Iran
Mesbah Shams - Endocrine and Metabolism Research Center, Shiraz University of Medical Science, Shiraz, Iran

Objective(s): Long-term consumption of pump inhibitors causes osteoporosis. Some possible mechanisms are gastrin over-secretion and hypochlorhydria. Octreotide is a somatostatin analog that inhibits the secretion of many hormones such as gastrin. This study aimed to assess the effects of pantoprazole on the bone when used with octreotide in an animal model. Materials and Methods: Forty-eight male Wistar rats were randomly assigned into ۴ groups: A) pantoprazole ۳ mg/Kg/day orally; B) Sandostatin LAR ۱ mg/month intramuscular injection; C) Pantoprazole and Sandostatin LAR; and D) Control group. After ۹۰ days of the experiment, bone densitometry was done and serum and urine samples were collected for analysis. Results: The results indicated a significant decrease in the global, spine, femur, and tibia bone mineral density (BMD) and bone mineral content (BMC) in the pantoprazole group compared to the control group (P<۰.۰۵). There was a significant increase in the levels of PTH, gastrin, and alkaline phosphatase (ALP) in the pantoprazole group compared to the control group (P<۰.۰۵). There was no significant difference in the serum levels of gastrin, PTH, ALP, and also BMD in the rats that received sandostatin+ pantoprazole or sandostatin alone, compared to the control group.Conclusion: This study showed that the pantoprazole-induced bone loss, through elevation of serum gastrin and PTH, was preventable by concomitant use of a long-acting somatostatin analog.

Bone Density, Octreotide, Osteoporosis, Pantoprazole, Parathyroid hormone